Molecule Information

General Information of the Molecule (ID: Mol05481)

• Name: LINC01564 ,Homo sapiens
• Molecule Type: Long non-coding RNA
• Sequence:
  CCAGGCGGCACATACATGATCCCAGACACCGAAGTAACCTCTGTCTCACTCCTCCACTTC
  CAGCAAGGGATGGAAAACAAACTGAAACTGGCTCAAGTGAATGCTCACTGGAAGGCTTAC
  TGGAAAACTTACTGGAAGGATGTGAGGACATGTTCGGGAATCTATTTGCAGAAAACATAT
  TCAGCCCTGTCCACCACAGCCAGCTGGCTGAAGAGCTCAAAAGGCAAGAAATCAGCAAGA
  GAGAGAGATGAAGCATGAGAAATGAGCAAAAAACACCCAGCACATCATAATCTTGGACAG
  TTTAGCAGTACATGAAAATAGATGGTCCTCGCCCCAAGGGACTGCAGTAACCCTGAATAA
  ACAGGATGTCTCTCACTTTTAGCAGTTCTTTCTGTGCTAGTATTGGGGAAATATATTTTT
  GGCTGCATGCAAAATGGTAAAAGACATCTATTAAGAAAATGAAAACAATGCTTCTGTTTT
  AGACGAAGCTTTTGAAGGTTTAAGGATCACCTATTTATTGACAAAATTGTTTCCGTGGCT
  TAAAAATAAAATACAAACAAATACTA

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Enzalutamide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Prostate cancer [ICD-11: 2C82.0] [1]

• Resistant Disease: Prostate cancer [ICD-11: 2C82.0]
• Resistant Drug: Enzalutamide
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LNCaP cells; Prostate; Homo sapiens (Human); CVCL_0395
• In Vitro Model: C4-2B cells; Prostate; Homo sapiens (Human); CVCL_4784
• Experiment for Molecule Alteration: Western blot
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: This gene is down-regulated in enzalutamide-resistance cells

Temozolomide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Glioma [ICD-11: 2A00.02] [2]

• Resistant Disease: Glioma [ICD-11: 2A00.02]
• Resistant Drug: Temozolomide
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: LN229 cells; Brain; Homo sapiens (Human); CVCL_0393
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: RT-qPCR; Western blot; RNA-binding protein immunoprecipitation (RIP) assay; Luciferase reporter assay; Immunoprecipitation; RNA pulldown assay
• Experiment for Drug Resistance: CCK8 assay; EdU assay; Flow cytometry; Iron detection assay
• Mechanism Description: LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.

References

• Ref 1: Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab ResistanceMol Cancer Ther. 2018 Feb;17(2):521-531. doi: 10.1158/1535-7163.MCT-17-0575. Epub 2017 Nov 20.
• Ref 2: Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):133-6. doi: 10.4103/0971-5851.158852.